[{"orgOrder":0,"company":"AFYX Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AFYX Therapeutics Achieves Primary Endpoint in Phase 2b Trial of Rivelin-CLO in Patients with Oral Lichen Planus","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Aleor Dermaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alembic Pharmaceuticals Announces Its Joint Venture, Aleor Dermaceuticals Receives USFDA Approval for Clobetasol Propionate Shampoo, 0.05%","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"May 2020","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Formosa Laboratories","pharmaFlowCategory":"D","amount":"$8.5 million","upfrontCash":"Undisclosed","newsHeadline":"Sosei Heptares to Receive US$2.5 Million Milestone Payment from Formosa Pharmaceuticals","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"March 2021","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III"},{"orgOrder":0,"company":"AFYX Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Study Published in the European Journal of Oral Sciences Features AFYX Therapeutics\u2019 Rivelin-CLO Patch for Treatment of Oral Lichen Planus","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2021","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II"},{"orgOrder":0,"company":"AFYX Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AFYX Therapeutics Presents Phase 2 Data of Rivelin-CLO at 2021 AAOM Virtual Conference","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II"},{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"Eyenovia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eyenovia Acquires U.S. Commercial Rights to APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension, 0.05%) from Formosa Pharmaceuticals","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"TAIWAN","productType":"Small molecule","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III"},{"orgOrder":0,"company":"Eyenovia","sponsor":"William Blair","pharmaFlowCategory":"D","amount":"$12.0 million","upfrontCash":"Undisclosed","newsHeadline":"Eyenovia Announces $12 Million Registered Direct Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III"},{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"AimMax Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Formosa Pharmaceuticals and AimMax Therapeutics to Present Phase 2 Trials Results of APP13007 for the Treatment after Cataract Surgery at ARVO 2022 Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"TAIWAN","productType":"Small molecule","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III"},{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"AimMax Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Formosa Pharmaceuticals and AimMax Therapeutics Announce Successful Top-Line Results from CPN-301 for the Treatment of Inflammation and Pain after Cataract Surgery","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"TAIWAN","productType":"Small molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III"},{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"Crist\u00e1lia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Formosa Pharmaceuticals Announces Licensing Agreement with Crist\u00e1lia, for the Commercialization of APP13007 for the Treatment of Inflammation and Pain Following Ocular Surgery","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"TAIWAN","productType":"Small molecule","productStatus":"Approved","date":"January 2024","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Formosa Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sosei Heptares to Receive US$2.5 Million Milestone Payment from Formosa Pharmaceuticals","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"March 2024","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III"},{"orgOrder":0,"company":"NovaBay Pharmaceuticals","sponsor":"Eyenovia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2024","url1":"","url2":"","graph1":"Immunology","graph2":"Approved"},{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"Tabuk Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Formosa Pharmaceuticals Announces Licensing Agreement with Tabuk Pharmaceuticals, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"TAIWAN","productType":"Small molecule","productStatus":"Approved","date":"May 2024","url1":"","url2":"","graph1":"Immunology","graph2":"Approved"},{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"AimMax Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Formosa Pharmaceuticals and AimMax Therapeutics Announce the NDA Submission to the US FDA for APP13007 for the Treatment of Post-Operative Inflammation and Pain following Ocular Surgery","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"TAIWAN","productType":"Small molecule","productStatus":"Approved","date":"May 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III"},{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"AimMax Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Formosa Pharmaceuticals and AimMax Therapeutics Receive FDA Approval for Clobetasol Propionate Ophthalmic Suspension 0.05%, for the Treatment of Post-Operative Inflammation and Pain Following Ocular Surgery","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"TAIWAN","productType":"Small molecule","productStatus":"Approved","date":"March 2024","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"}]
Find Clinical Drug Pipeline Developments & Deals for Clobetasol
Tabuk gains exclusive rights to the commercialization of clobetasol propionate ophthalmic suspension, APP13007, a patented innovative medicine for the treatment of inflammation and pain following ocular surgery in key regions of the Middle East and North Africa (MENA).
Under the agreement,NovaBay will market Eyenovia’s clobetasol propionate ophthalmic suspension, a steroid indicated for the treatment of inflammation and pain following ocular surgery, through its U.S. physician-dispensed channel.
APP13007 (clobetasol propionate) is a nanoparticle formulation of a steroid in development for the treatment of inflammation and pain after cataract surgery. Sosei Heptares will receive undisclosed milestone payments based on progression of Activus' pipeline.
APP13007 (clobetasol propionate) is a nanoparticle ophthalmic formulation of a steroid. It is approved for the treatment of post-operative inflammation and pain following ocular surgery.
Under the agreement, Cristália gets exclusive Brazilian rights for the commercialization of APP13007 (clobetasol propionate ophthalmic nanosuspension) for the treatment of inflammation and pain following ocular surgery.
The net proceeds will fund commercialization of a post-ophthalmic surgery product, APP13007 (clobetasol propionate), developed using Formosa’s proprietary APNT nanoparticle formulation platform, and for the manufacturing automation activities for the Optejet® device.
Through the acquisition, Eyenovia has gained the exclusive U.S. rights to distribute and sell APP13007 (clobetasol propionate ophthalmic nanosuspension), a potent steroid for reducing the inflammation and pain associated with ocular surgery, which is under review by FDA.
APP13007 (clobetasol propionate ophthalmic nanosuspension) is expected to provide ophthalmologists and ocular surgery patients with a compelling, rapid and sustained, and more convenient postoperative anti-inflammatory and pain relief solution.
There were 26.5% of subjects who showed sustained anterior chamber cell (ACC) count = 0 (inflammation free) from post-operative day 8 (POD8) through POD15 in the APP13007 (clobetasol propionate) arm as compared to 5.1% in the placebo arm (p<0.001).
Data showed statisticallly-significant and clinically-meaningful improvement of inflammation and pain with twice-daily APP13007 compared to matching placebo, a regimen that is being evaluated in ongoing Phase 3 studies.